{"id":3005,"date":"2026-09-09T07:00:00","date_gmt":"2026-09-09T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3005"},"modified":"2026-09-09T19:39:35","modified_gmt":"2026-09-09T23:39:35","slug":"opgx-best1-shows-early-signals-in-five-treated-participants","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3005","title":{"rendered":"OPGx-BEST1 Shows Early Signals in Five Treated Participants"},"content":{"rendered":"

Evidence<\/strong> Company disclosure · Discovery<\/strong> September 9, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Uncertain<\/p>\n

\"OPGx-BEST1<\/p>\n

Summary<\/h4>\n

Opus Genetics reported low-dose Cohort 1 results from the open-label Phase I\/II BIRD-1 study of subretinal OPGx-BEST1 in five adults with BEST1-related retinal disease. All five improved on at least one visual-function measure, four had structural improvement and no serious adverse event or dose-limiting toxicity was reported. FDA also agreed that a prespecified microperimetry threshold combined with a patient-reported outcome could serve as a potential pivotal endpoint. The dataset is too small, heterogeneous and short to establish efficacy.<\/p>\n

What Happened<\/h4>\n

Three participants with Best vitelliform macular dystrophy had three months of follow-up and two with autosomal-recessive bestrophinopathy had six months. Three of five improved on best-corrected visual acuity, three of four evaluable participants improved on microperimetry, two of three BVMD participants showed reduced vitelliform material and both ARB participants showed reduced intraretinal fluid. Each participant was counted as clinically improved if any of several functional measures changed. Eight participants are enrolled at the higher dose, with six-month data expected in the second quarter of 2027.<\/p>\n

Deep Analysis<\/h4>\n

Early biological activity across BEST1 phenotypes:<\/strong> Concordant functional or structural change in every treated participant is compatible with successful RPE transduction and BEST1 restoration. Greater gains in less advanced disease may be biologically coherent. Counterevidence includes mixed diagnoses, different follow-up times, multiple measures, no untreated eye comparison in the headline analysis and strong susceptibility to test-retest and learning effects.<\/p>\n

Regulatory endpoint alignment is useful but conditional:<\/strong> FDA feedback may reduce endpoint uncertainty and support rapid pivotal planning. However, an acceptable potential endpoint is not an agreed registrational program, and the underlying Type C minutes are not public. Manufacturing completion, dose selection, randomization, masking and patient-reported outcome validation remain required.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: five low-dose participants; no serious adverse event or dose-limiting toxicity; multi-domain functional or structural changes; eight higher-dose participants; FDA Type C feedback. Missing facts: individual trajectories, fellow-eye controls, confidence intervals, durability, inflammation, steroid burden, vector shedding, neutralizing antibodies and full agency minutes. Upgrade evidence would be consistent six-month higher-dose improvement against prespecified controls.<\/p>\n

Company and Product Background<\/h4>\n

Opus Genetics develops gene therapies for inherited retinal diseases. BEST1 mutations impair retinal pigment epithelium ion and fluid handling, causing vitelliform lesions, intraretinal fluid and progressive central vision loss in dominant BVMD or recessive bestrophinopathy. No therapy corrects the underlying defect.<\/p>\n

OPGx-BEST1 uses an adeno-associated viral vector delivered subretinally to provide a functional BEST1 copy to retinal pigment epithelial cells. Local delivery can place vector near the intended tissue but requires surgery and exposes patients to inflammation, detachment and procedure-related risk. Dominant disease may also require adequate expression to overcome mutant-protein effects.<\/p>\n

InSilens Take<\/h4>\n

The report supplies plausible first-in-human biological activity and a clearer regulatory path, but the five-person signal should remain uncertain. “Improved on any measure” is vulnerable to multiplicity and learning effects, particularly in open-label retinal testing. The next decisive step is prespecified, durable, dose-responsive functional improvement in a controlled cohort with full ocular safety.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — the first disclosed clinical signal for a gene-replacement program spanning two BEST1 phenotypes, including regulatory endpoint feedback<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nUncertain — findings are encouraging but cannot separate treatment effect from variability in five open-label cases<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — cohort, dose, follow-up and headline measures disclosed by the sponsor<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nLow-moderate — multiplicity, heterogeneity and short follow-up dominate uncertainty<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Opus Genetics reported low-dose Cohort 1 results from the open-label Phase I\/II BIRD-1 study of subretinal OPGx-BEST1 in five adults with BEST1-related retinal disease. All five improved on at least one visual-function measure, four…<\/p>\n","protected":false},"author":1,"featured_media":3016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[649,648,647],"class_list":["post-3005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-best1","tag-opgx-best1","tag-opus-genetics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3005"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005\/revisions"}],"predecessor-version":[{"id":3025,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005\/revisions\/3025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3016"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}